BeiGene CEO John Oyler has long said China has all the world-class science and entrepreneurial ambition necessary to become a biotech hotbed. All that’s missing is the kind of venture capital interest startups enjoy on the other side of the Pacific, he said. Now his company, at work on a pipeline of cancer treatments, is bucking that trend, hauling in a $97 million round and speeding ahead in the clinic.

…read more

Source: China’s BeiGene banks $97M to get its cancer drugs into the clinic


0 No comments